LYCOS RETRIEVER 
Imitrex: Patients
built 634 days ago
Imitrex Tablets should not be taken by patients receiving treatment with monoamine oxidase inhibitors (MAOIs), or used within two weeks of stopping therapy with MAOIs. Imitrex should not be used in patients with ischemic heart disease, symptoms or signs consistent with ischemic heart disease, or Prinzmetal's angina because of rare reports of coronary vasospasm. Patients with risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or are postmenopausal or a male over 40) should be evaluated by a physician to determine if Imitrex is appropriate therapy.
Source:
Overall, Imitrex was significantly more effective than placebo for headache relief (Tables 2 and 3). Imitrex improved functional disability (most patients given Imitrex could function normally within 30 minutes compared with 60 minutes for placebo) and reduced ipsilateral conjunctival injection (present in 36% of patients 15 minutes after Imitrex administration compared with 74% for placebo). Data for other symptoms were not reported.
Source:
MORE ABOUT
Patients